FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801117488> ?p ?o ?g. }

• W2801117488 endingPage "47" @default.
• W2801117488 startingPage "39" @default.
• W2801117488 abstract "ObjectivesThis randomized, double-blind, placebo-controlled, cross-over, Phase II dose-ranging study investigated the efficacy and safety of GP MDI (glycopyrronium administered by metered dose inhaler formulated using co-suspension delivery technology) compared with an open-label active comparator, salmeterol dry powder inhaler (SAL DPI), in subjects with intermittent or mild-to-moderate persistent asthma.MethodsSubjects were randomized to receive five of seven treatments (GP MDI 28.8, 14.4, 7.2, 3.6, and 1.9 μg, placebo MDI, and SAL DPI 50 μg), each for a 14-day period. The primary endpoint was peak change from baseline in forced expiratory volume in 1 s (FEV1) on Day 15. Secondary endpoints included additional lung function parameters and symptoms (Asthma Control Questionnaire-5). Safety was monitored throughout.ResultsOf 248 subjects randomized, 211 completed the study. All doses of GP MDI resulted in significant improvements in the primary endpoint compared with placebo MDI in a dose-ordered fashion (range 85–155 mL, p < .0001), without appreciable differences between the two highest doses of GP MDI (28.8 and 14.4 μg) and SAL DPI 50 μg. Improvements in secondary lung function endpoints and symptoms were generally dose-ordered, with GP MDI 28.8 μg showing the greatest improvements. Similar results were observed when endpoints were analyzed based on subjects' background use of inhaled corticosteroids (yes/no). All GP MDI doses were well tolerated with no evidence of a dose-related effect on adverse events.ConclusionsThe results of this study suggest that GP MDI could offer an important treatment option for maintenance therapy of asthma, and warrants further investigation in Phase III clinical trials." @default.
• W2801117488 created "2018-05-17" @default.
• W2801117488 creator A5004903602 @default.
• W2801117488 creator A5011502862 @default.
• W2801117488 creator A5022001894 @default.
• W2801117488 creator A5025257736 @default.
• W2801117488 creator A5027975503 @default.
• W2801117488 creator A5039740362 @default.
• W2801117488 creator A5077419098 @default.
• W2801117488 creator A5089983710 @default.
• W2801117488 creator A5091669818 @default.
• W2801117488 date "2018-06-01" @default.
• W2801117488 modified "2023-09-27" @default.
• W2801117488 title "Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial" @default.
• W2801117488 cites W1890874870 @default.
• W2801117488 cites W1989134881 @default.
• W2801117488 cites W2009191674 @default.
• W2801117488 cites W2039439214 @default.
• W2801117488 cites W2066842697 @default.
• W2801117488 cites W2067736395 @default.
• W2801117488 cites W2097678159 @default.
• W2801117488 cites W2102583457 @default.
• W2801117488 cites W2102804949 @default.
• W2801117488 cites W2108678383 @default.
• W2801117488 cites W2119147796 @default.
• W2801117488 cites W2126325768 @default.
• W2801117488 cites W2150634254 @default.
• W2801117488 cites W2150866838 @default.
• W2801117488 cites W2161775889 @default.
• W2801117488 cites W2317895461 @default.
• W2801117488 cites W2337193334 @default.
• W2801117488 cites W2508659471 @default.
• W2801117488 cites W2558903543 @default.
• W2801117488 cites W2568255753 @default.
• W2801117488 cites W2591678263 @default.
• W2801117488 cites W2613139212 @default.
• W2801117488 cites W2746473595 @default.
• W2801117488 cites W2761239349 @default.
• W2801117488 doi "https://doi.org/10.1016/j.rmed.2018.04.013" @default.
• W2801117488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29858000" @default.
• W2801117488 hasPublicationYear "2018" @default.
• W2801117488 type Work @default.
• W2801117488 sameAs 2801117488 @default.
• W2801117488 citedByCount "15" @default.
• W2801117488 countsByYear W28011174882019 @default.
• W2801117488 countsByYear W28011174882020 @default.
• W2801117488 countsByYear W28011174882021 @default.
• W2801117488 countsByYear W28011174882022 @default.
• W2801117488 countsByYear W28011174882023 @default.
• W2801117488 crossrefType "journal-article" @default.
• W2801117488 hasAuthorship W2801117488A5004903602 @default.
• W2801117488 hasAuthorship W2801117488A5011502862 @default.
• W2801117488 hasAuthorship W2801117488A5022001894 @default.
• W2801117488 hasAuthorship W2801117488A5025257736 @default.
• W2801117488 hasAuthorship W2801117488A5027975503 @default.
• W2801117488 hasAuthorship W2801117488A5039740362 @default.
• W2801117488 hasAuthorship W2801117488A5077419098 @default.
• W2801117488 hasAuthorship W2801117488A5089983710 @default.
• W2801117488 hasAuthorship W2801117488A5091669818 @default.
• W2801117488 hasBestOaLocation W28011174881 @default.
• W2801117488 hasConcept C126322002 @default.
• W2801117488 hasConcept C142724271 @default.
• W2801117488 hasConcept C168563851 @default.
• W2801117488 hasConcept C197934379 @default.
• W2801117488 hasConcept C203092338 @default.
• W2801117488 hasConcept C204787440 @default.
• W2801117488 hasConcept C27081682 @default.
• W2801117488 hasConcept C2776042228 @default.
• W2801117488 hasConcept C2776312127 @default.
• W2801117488 hasConcept C2777419714 @default.
• W2801117488 hasConcept C2780261241 @default.
• W2801117488 hasConcept C2780667556 @default.
• W2801117488 hasConcept C2991744798 @default.
• W2801117488 hasConcept C42219234 @default.
• W2801117488 hasConcept C71924100 @default.
• W2801117488 hasConceptScore W2801117488C126322002 @default.
• W2801117488 hasConceptScore W2801117488C142724271 @default.
• W2801117488 hasConceptScore W2801117488C168563851 @default.
• W2801117488 hasConceptScore W2801117488C197934379 @default.
• W2801117488 hasConceptScore W2801117488C203092338 @default.
• W2801117488 hasConceptScore W2801117488C204787440 @default.
• W2801117488 hasConceptScore W2801117488C27081682 @default.
• W2801117488 hasConceptScore W2801117488C2776042228 @default.
• W2801117488 hasConceptScore W2801117488C2776312127 @default.
• W2801117488 hasConceptScore W2801117488C2777419714 @default.
• W2801117488 hasConceptScore W2801117488C2780261241 @default.
• W2801117488 hasConceptScore W2801117488C2780667556 @default.
• W2801117488 hasConceptScore W2801117488C2991744798 @default.
• W2801117488 hasConceptScore W2801117488C42219234 @default.
• W2801117488 hasConceptScore W2801117488C71924100 @default.
• W2801117488 hasLocation W28011174881 @default.
• W2801117488 hasLocation W28011174882 @default.
• W2801117488 hasOpenAccess W2801117488 @default.
• W2801117488 hasPrimaryLocation W28011174881 @default.
• W2801117488 hasRelatedWork W1735104919 @default.
• W2801117488 hasRelatedWork W2035105554 @default.
• W2801117488 hasRelatedWork W2062333112 @default.
• W2801117488 hasRelatedWork W2150652273 @default.

• next